Assert-IQ vs Rapid RV/LV
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your clinical focus is on diagnosing and managing patients with suspected, often elusive, heart rhythm disorders over an extended period. This tool is ideal for capturing intermittent arrhythmias that may not be detected by shorter-term monitoring, providing continuous data for up to six years to inform long-term management strategies.
View Assert-IQ →Choose Rapid RV/LV if…
Choose Rapid RV/LV if your priority is the immediate and objective assessment of pulmonary embolism severity from CTPA scans, particularly in acute care settings. This AI-powered solution provides rapid, automated right and left ventricle ratio measurements, enabling quick clinical decision-making and efficient patient triage for suspected PE cases.
View Rapid RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | Rapid RV/LV |
|---|---|---|
| Pricing | Unknown | Contact vendor for pricing information. |
| Deployment | Subcutaneously implanted device with mobile app connectivity | Unknown |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Assert-IQAssert-IQ offers comprehensive usability for both patients and clinicians. Patients benefit from a minimally invasive device, a mobile app (myMerlin) for symptom logging, and remote data transmission. Clinicians can remotely program the device, reducing the need for in-person clinic visits and streamlining workflow.
Clinical Value
Rapid RV/LVRapid RV/LV provides critical, time-sensitive clinical value by offering rapid, AI-powered assessment of pulmonary embolism severity through automated RV/LV ratio measurements from CTPA scans. This capability significantly reduces time to diagnosis, standardizes measurements, and improves risk stratification for an acute, life-threatening condition.
Pricing & Value
TieBoth Assert-IQ and Rapid RV/LV utilize opaque enterprise pricing models, requiring direct contact with the vendor for details, and neither offers a free trial. Without specific pricing information or comparative cost-effectiveness studies, it is impossible to determine which tool offers better value.
Enterprise Readiness
Assert-IQBoth tools are FDA-cleared, HIPAA compliant, and offer hybrid deployment. However, Assert-IQ is backed by Abbott Medical, a global healthcare leader with over a century of experience, vast resources, and established enterprise relationships, offering comprehensive 'End to End Solutions' for large health systems.
Innovation
Assert-IQAssert-IQ demonstrates multifaceted innovation with its longest-lasting Bluetoothu00ae-enabled ICM (up to 6 years), advanced AI algorithms that significantly reduce false positives while maintaining high sensitivity, and 'IQ Insights' for holistic cardiovascular health monitoring. It also features remote programmability, enhancing patient management.
Support & Docs
Assert-IQAbbott provides extensive support and documentation for Assert-IQ, including detailed clinician and patient manuals, help guides for its remote monitoring network, and patient-facing support for mobile app setup (SyncUP). Direct technical support contact information is also readily available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | Rapid RV/LV |
|---|---|---|
| Name | Assert-IQ | Rapid RV/LV |
| Company | Abbott Medical | RapidAI (formerly iSchemaView) |
| Description | The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | Rapid RV/LV by RapidAI is an FDA-cleared AI tool for rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. |
| Categories | Cardiology AI, Clinical Decision Support & Reference | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Internal Medicine | Cardiology, Pulmonology, Radiology |
| Key Features (partial) | Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Bluetoothu00ae Low Energy data transmission | AI-powered analysis of CTPA images, Automated measurement of right and left ventricle diameters, Calculation of RV/LV ratio |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and Rapid RV/LV.